Phase 3 Study Randomized Evaluating the Efficacy of Auriculotherapy in Patients With Musculoskeletal Pain by Aromatase Inhibitors

Inclusion Criteria: * Patient over 18 years of age * Patients with anti-aromatases in adjuvant treatment of breast cancer * Menopausal women * Treatment with aromatase inhibitors (anti-aromatase, AA) initiated for more than 3 months. In the case of a change in anti-aromatase, the last treatment must be started for more than 3 months. * Musculoskeletal pain appearing or increased under AA: * Overall pain score of QCD ≥3 (on a scale of 0 to 10) * Pain on at least 2 sites * Pain for at least 3 months * History of radiotherapy and / or adjuvant chemotherapy authorized * Patients may have received tamoxifen * Patient affiliated to a social security system * Patient mastering the French language and able to complete the evaluation questionnaires * Free and Informed Consent Exclusion Criteria: * Patients who have already undergone treatment in auriculotherapy for the same indication * Patient benefiting at the same time from a PNCAVT (acupuncture or homeopathy) for musculoskeletal pain * Wearing hearing aids hindering the placement of semi-permanent needles (ASP) * Wearing of a valve prosthesis * Patient under guardianship or unable to give informed consent * Patient unable to undergo medical follow-up for geographical, social or psychopathological reasons